Pneumonia is a leading cause of death and hospitalization, costing health care systems billions of dollars and an estimated 600,000 adult deaths worldwide each year. Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and the term describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections. Although all age groups may be affected, the highest rate of pneumococcal disease occurs in young children and older adults. In addition, persons suffering from a wide range of chronic conditions (eg, diabetes, cardiovascular disease) and immune deficiencies are at increased risk.
There is an idea within the coronavirus research field that there is some kind of T cell abnormality in critically ill COVID-19 patients, but specific details have not yet been clarified. To shed light on the problem, a research collaboration based in Kumamoto University (Japan) has performed a genetic analysis of T cells from lung tissue of COVID-19 patients.
The cell membrane is the cell's outermost line of defense against SARS-CoV-2, the novel coronavirus responsible for COVID-19 disease.
Jacqueline Kimmey speaks to AZoLifeSciences about her research into bacterial pneumonia and the genes that drive its spread from the lungs into the blood.
Researchers have designed a laboratory test that can detect the microbial miscreant affecting patients hospitalized with serious infections in just six hours.
Gomila et al. recently uploaded a study to the preprint server medRxiv* (November 2020), aiming to utilize MALDI-TOF MS to analyze the sera of patients infected with SARS-CoV-2 in a range of disease severity states.
A team of Duke University researchers has developed a lab-grown living lung model that mimics the tiny air sacs of the lungs where coronavirus infection and serious lung damage take place. This advance has enabled them to watch the battle between the SARS-CoV-2 coronavirus and lung cells at the finest molecular scale.
'Mini-lungs' grown from tissue donated to Cambridge hospitals has provided a team of scientists from South Korea and the UK with important insights into how COVID-19 damages the lungs.
SARS-CoV-2 continues to cause an ongoing pandemic as of October 2020, with over 35 million reported cases and over 1 million deaths around the world.
Scientists have discovered a new cellular pathway that can be targeted with a naturally occurring medication to activate the regeneration of lung tissue.
For the first time, researchers have discovered how antibiotic resistance genes are spreading, at a continental scale, via bacterial plasmids in the hospital superbug, Klebsiella pneumoniae.
Researchers have identified a druggable pocket in the SARS-CoV-2 Spike protein that could be utilized to prevent the virus from infecting human cells.
A major percentage of COVID-19 cases have become so severe that hospital admissions have become mandatory for both monitoring and treatment.
Scientists are trying to figure out how SARS-CoV-2 leads to a range of symptoms that appear to persist long after the active viral infection.
Antibiotics are among the most important discoveries of modern medicine and have saved millions of lives since the discovery of penicillin almost 100 years ago.
The human microbiota plays an important role in health and well-being by assisting in digestion, producing nutrients, resisting invading pathogens and regulating metabolism and the immune system.
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.
Scientists at Nanyang Technological University, Singapore (NTU Singapore) have developed a synthetic peptide that can make multidrug-resistant bacteria sensitive to antibiotics again when used together with traditional antibiotics, offering hope for the prospect of a combination treatment strategy to tackle certain antibiotic-tolerant infections.
A team of researchers showed that artificial intelligence (AI) could help predict the type of bacteria that caused the infection in patients with pneumonia.
Approximately 5% of people with Covid-19 progress to a severe or critical form, including the development of severe pneumonia that progresses to acute respiratory distress syndrome.
Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial to evaluate the safety and efficacy of an antiviral drug, DAS181, as a possible treatment for hospitalized patients with severe COVID-19.